Abstract
Multiple myeloma (MM) is a bone marrow cancer of resident plasma cells that affects 125,000 patients in the U.S. with about 30,000 new cases per year. Its signature is the clonal proliferation of a single plasma cell that secretes a patient specific monoclonal immunoglobulin (M-Ig). Targeting the M-Ig in patient serum could allow sensitive and noninvasive identification of minimal residual disease in multiple myeloma. Aptamers, which are single-stranded oligonucleotides with affinity and specificity to a target molecule, have recently been introduced as affinity reagents for recognition of MM M-Igs. Here we exploit microfluidic SELEX technology to enable rapid and efficient generation of aptamers against M-Ig proteins from MM patients. We first characterize the technology by isolating aptamers with affinity towards the monoclonal antibody rituximab as a model M-Ig and then apply the technology to isolating aptamers specifically targeting M-Igs obtained from serum samples of MM patients. We demonstrate that high-affinity DNA aptamers (KD < 50 nM) for M-Ig proteins from a patient sample could be isolated via microfluidic SELEX within approximately 12 h and using less than 100 micrograms of patient M-Ig. Such aptamers can potentially be used in personalized monitoring of minimal residual disease in MM patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
C. Bai, X. Meng, K. Wen, M. Citartan, C. Wang, Shifeng Yu, and Qiao Lin. 2022. ‘surface acoustic wave-assisted microfluidic isolation of aptamers’, Microfluid. Nanofluid., 26: 1–10
H. Bergen, S. Robert, A. Dasari, J.R. Dispenzieri, M. Mills, R.C. Ramirez-Alvarado, D.F. Tschumper, D.R. Jelinek, Barnidge, L.Murray David. 2016. ‘Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration’, Clinical Chemistry, 62: 243 – 51
J.R. Brestoff, K. Angus Toland, A.J. Afaneh, B. Qavi, P. Press, F. Westervelt, Kreisel, and Anjum Hassan. 2018. ‘bone marrow biopsy needle type affects core biopsy specimen length and quality and aspirate hemodilution’, American Journal of Clinical Pathology
E. Cid Ruzafa, Javier, R.F. Merinopoulou, P. Baggaley, W. Leighton, D. Werther, Felici, Andrew Cox. 2016. ‘patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model’, Pharmacoepidemiol. Drug Saf., 25: 871–879
J.P. Hilton, T. Olsen, J. Kim, J. Zhu, ThaiHuu Nguyen, M. Barbu, Renjun Pei, Milan Stojanovic, and Qiao Lin. 2015. ‘Isolation of thermally sensitive protein-binding oligonucleotides on a microchip’, Microfluidics and Nanofluidics
J. Hoinka, R. Backofen, M. Teresa, Przytycka, ‘AptaSUITE: a full-featured Bioinformatics Framework for the Comprehensive analysis of aptamers from HT-SELEX experiments’. Mol. Therapy-Nucleic Acids 11, 515–517 (2018)
C.-J. Huang, Hsin-I. Lin, S.-C. Shiesh, Gwo-Bin Lee, ‘Integrated microfluidic system for rapid screening of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX)’. Biosens. Bioelectron. 25, 1761–1766 (2010)
E. Iaccino, S. Mimmi, V. Dattilo, F. Marino, P. Candeloro, A.D. Loria, D. Marimpietri, A. Pisano, F. Albano, Eleonora Vecchio. 2017. ‘monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes’, Mol. Cancer, 16: 159
J. Kim, T.R. Olsen, J. Zhu, J.P. Hilton, K.-A. Yang, R. Pei, M.N. Stojanovic, Qiao Lin. 2016. ‘Integrated Microfluidic isolation of Aptamers using Electrophoretic Oligonucleotide Manipulation’, Sci. Rep., 6: 26139
M. Korthals, N. Sehnke, R. Kronenwett, I. Bruns, J. Mau, F. Zohren, R. Haas, Guido Kobbe, and Roland Fenk, ‘the level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter’. Biol. Blood Marrow Transplant. 18, 423–431 (2012). e3
S. Kumar, B. Paiva, K.C. Anderson, B. Durie, O. Landgren, P. Moreau, N. Munshi, S. Lonial, Joan Bladé, and Maria-Victoria Mateos. 2016. ‘International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma’, Lancet Oncol., 17: e328–e346
R.A. Kyle, ‘diagnostic criteria of multiple myeloma’. Hematol. Oncol. Clin. N. Am. 6, 347–358 (1992)
R.A. Kyle, S.V. Rajkumar. 2009. ‘Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma’, Leukemia, 23: 3
R.A. Kyle, ‘the monoclonal gammopathies’. Clin. Chem. 40, 2154–2161 (1994)
N. Lee, S.Y. Moon, S.Y. Kim, S.M. Hwang, H.K. Park, S.-M. Bang, J.H. Lee, S.-S. Yoon, D.S. Lee, ‘analysis of CD138 + plasma cell percentage in bone marrow section using image Analyzer: discrepancies of bone marrow plasma cell count between aspiration and Biopsy Section in multiple myeloma’. Clin. Lymphoma Myeloma Leuk. 15, e96 (2015)
J. Martinez-Lopez, J.J. Lahuerta, F. Pepin, M. González, S. Barrio, R. Ayala, Noemí M.A. Puig, B. Montalban, Paiva, and Li Weng. 2014a. ‘Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma’, Blood, 123: 3073-79
J. Martinez-Lopez, J.J. Lahuerta, F. Pepin, M. González, S. Barrio, R. Ayala, Noemí M.A. Puig, B. Montalban, Paiva, and Li Weng. 2014b. ‘Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma’, Blood: blood-2014-01-550020
T.R. Olsen, K.-A. Claudia Tapia-Alveal, X. Yang, L.J. Zhang, N. Pereira, R. Farmakidis, M.N. Pei, Stojanovic, Qiao Lin. 2017. ‘Integrated Microfluidic Selex using free solution Electrokinetics’, J. Electrochem. Soc., 164: B3122–B3129
T. Olsen, J. Zhu, J. Kim, R. Pei, M.N. Stojanovic, Q. Lin. 2016. ‘an Integrated Microfluidic SELEX Approach using combined Electrokinetic and Hydrodynamic Manipulation’, Journal of Laboratory Automation: 2211068216659255
A.C. Rawstron, J.Anthony Child, M. Ruth, F.E. de Tute, W.M. Davies, S.E. Gregory, A.J. Bell, N. Szubert, M.T. Navarro-Coy, Drayson, Sylvia Feyler. 2013. ‘minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council myeloma IX study’, J. Clin. Oncol., 31: 2540–2547
M.E. Reff, S. Kristin Carner, Karen, P.C. Chambers, J.E. Chinn, R. Leonard, R.A. Raab, N. Newman, Hanna, R.Anderson Darrell. 1994. ‘depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20’
A. Romano, G.A. Palumbo, N.L. Parrinello, C. Conticello, M. Martello, Carolina Terragna. 2019. ‘the minimal residual disease within the bone marrow of multiple myeloma: caveats, clinical significance and future perspectives’, Front. Oncol., 9: 699
A. Sinha, P. Gopinathan, Y.-D. Chung, H.-Y. Lin, K.-H. Li, H.-P. Ma, P.-C. Huang, S.-C. Shiesh, L. Gwo-Bin, ‘an integrated microfluidic platform to perform uninterrupted SELEX cycles to screen affinity reagents specific to cardiovascular biomarkers’. Biosens. Bioelectron. 122, 104–112 (2018)
C. Tapia-Alveal, T.R. Olsen, S.Worgall Tilla, ‘personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum’. Commun. biology 3, 1–12 (2020)
A.D. Tatsas, H. Madan, H. Jagasia, Chen, L.McCurley Thomas, ‘monitoring residual myeloma high-resolution Serum/Urine electrophoresis or marrow biopsy with immunohistochemical analysis?‘. Am. J. Clin. Pathol. 134, 139–144 (2010)
A. Udd, Kyle, M. Tanya, Spektor, R.Berenson James. 2017. ‘Monitoring Multiple Myeloma’, Clinical advances in hematology & oncology: H&O, 15: 951 – 61
J.K. van de Velde, Helgi, G. Xiangyang Liu, A. Chen, W. Cakana, Deraedt, and Martine Bayssas. 2007. ‘Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma’, Haematologica, 92: 1399 – 406
R. Vij, A. Mazumder, M. Klinger, D.O.‘Dea, J. Paasch, T. Martin, L. Weng, J. Park, M. Fiala, M. Faham, Jeffrey Wolf. 2014. ‘deep sequencing reveals Myeloma cells in Peripheral Blood in Majority of multiple myeloma patients’, Clin. Lymphoma Myeloma Leuk., 14: 131 – 39.e1
A. Wei, D. Westerman, F. Feleppa, M. Trivett, and Surender Juneja, ‘bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma’. Haematologica 90, 1147–1149 (2005)
S. Wildner, S. Huber, C. Regl, C.G. Huber, U. Lohrig, Gabriele Gadermaier. 2019. ‘aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab’, Sci. Rep., 9: 1–14
Acknowledgements
This study was supported in part by the National Institutes of Health grants R33CA196470, TL1 TR001875, and UL1TR001873.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Statements and declarations
Nothing to declare.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Olsen, T.R., Tapia-Alveal, C., Wen, K. et al. Microfluidic isolation of aptamers with affinity towards multiple myeloma monoclonal immunoglobulins. Biomed Microdevices 25, 3 (2023). https://doi.org/10.1007/s10544-022-00643-x
Accepted:
Published:
DOI: https://doi.org/10.1007/s10544-022-00643-x